🔬 Exciting Collaboration Alert! 🌟 We’re thrilled to announce a groundbreaking partnership between DevsHealth and the Germans Trias i Pujol Research Institute (IGTP). Together, we’re embarking on a mission to develop new antibiotics aimed at combating hospital-acquired infections caused by multi-resistant Staphylococcus aureus. 🧫 Staphylococcus aureus is notorious for causing severe infections and is recognized by the WHO as a high-priority pathogen due to its resistance to existing antibiotics. This collaboration is not just a step forward in medical science; it’s a leap towards safeguarding public health. 💡 By leveraging DevsHealth’s innovative DeepTech platform and IGTP’s extensive bacterial collection, we aim to discover drugs that can outsmart resistance mechanisms. Our combined expertise signifies hope for effective treatments against these formidable infections. 🤝 This partnership aligns perfectly with our vision to industrialize drug development and create the largest pipeline for infectious diseases. It’s a fusion of technology and science where AI meets years of research to fast-track the discovery of life-saving drugs. Stay tuned as we embark on this exciting journey. Together, we can make a difference! #DevsHealth #IGTP #Innovation #Healthcare #Antibiotics #Collaboration #PublicHealth #AMR https://lnkd.in/dBCj_wCK
DevsHealth
Biotecnología
La Garriga, Catalonia 617 seguidores
At DevsHealth, we leverage our advanced DeepTech platform to enhance the development of anti-infective treatments.
Sobre nosotros
DevsHealth is a pioneering DeepTech company that industrializes drug discovery, transforming it into a scalable endeavor. Our proprietary technology platform, which integrates AI, real-world data (RWD), and molecular modeling, is at the forefront of revolutionizing the development of new anti-infective treatments, including antiviral and antibiotic drugs. Our platform and business model enable us to streamline the initial stages of drug development, significantly reducing the time, risk, and cost typically associated with traditional methods. This computational model-based approach not only accelerates the process but also enhances the precision of our drug discovery efforts. As a company driven by impact, we extend our focus to tackle neglected infectious diseases, aligning with our commitment to promote health and well-being for all ages, in accordance with the third Sustainable Development Goal. At DevsHealth, we are not just developing treatments; we are redefining the paradigm of drug development to make a scalable and sustainable impact on global health.
- Sitio web
-
https://devshealth.com
Enlace externo para DevsHealth
- Sector
- Biotecnología
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- La Garriga, Catalonia
- Tipo
- De financiación privada
- Fundación
- 2021
- Especialidades
- bioinformatics, drug discovery, drug development, precision medicine, computational drug development, ai, artificial intelligence, antibiotics y anti-virals
Ubicaciones
-
Principal
Cómo llegar
C. Vulcà, 67
La Garriga, Catalonia 08530, ES
Empleados en DevsHealth
Actualizaciones
-
DevsHealth ha compartido esto
Big News from DevsHealth! 🚀 We are excited to share that DevsHealth has been certified by Enisa con el emprendimiento innovador , Spain’s national innovation agency. This certification marks a pivotal moment for us: 🌟 Investor Attraction: With ENISA’s certification, DevsHealth stands out as a prime opportunity for investors. Expect enhanced tax incentives and a streamlined process that makes investing in our vision more appealing than ever. 🌐 Welcoming Global Investments: This certification eases the way for foreign investors to contribute to our journey, fostering a global community around our innovative health solutions. ✨ Acknowledgment of Promise: Being recognized by ENISA signifies that DevsHealth is seen as a company with immense promise and potential for growth. It’s a testament to our dedication and forward-thinking approach in the health tech sector. 🎖️ Advantages for Us: Beyond the benefits for investors, this certification provides us with additional advantages, reinforcing our status as a leading innovator in healthcare technology. Let’s celebrate this achievement as we continue to push the boundaries of what’s possible in healthcare. Together, we’re making strides toward a healthier future! #DevsHealth #ENISACertification #HealthTech #Innovation #InvestmentOpportunity
-
-
Big News from DevsHealth! 🚀 We are excited to share that DevsHealth has been certified by Enisa con el emprendimiento innovador , Spain’s national innovation agency. This certification marks a pivotal moment for us: 🌟 Investor Attraction: With ENISA’s certification, DevsHealth stands out as a prime opportunity for investors. Expect enhanced tax incentives and a streamlined process that makes investing in our vision more appealing than ever. 🌐 Welcoming Global Investments: This certification eases the way for foreign investors to contribute to our journey, fostering a global community around our innovative health solutions. ✨ Acknowledgment of Promise: Being recognized by ENISA signifies that DevsHealth is seen as a company with immense promise and potential for growth. It’s a testament to our dedication and forward-thinking approach in the health tech sector. 🎖️ Advantages for Us: Beyond the benefits for investors, this certification provides us with additional advantages, reinforcing our status as a leading innovator in healthcare technology. Let’s celebrate this achievement as we continue to push the boundaries of what’s possible in healthcare. Together, we’re making strides toward a healthier future! #DevsHealth #ENISACertification #HealthTech #Innovation #InvestmentOpportunity
-
-
Dengue fever, a challenge historically overlooked by high-income nations, is now gaining attention as its presence grows in the EU and USA. At DevsHealth, we've always been driven by the impact we can make. That's why, nearly a year ago, we began developing treatments for flavivirus infections, including dengue. We're excited to share our progress and hope we will announce initial results soon. #Dengue #DrugDiscovery #NeclectedDiseases
The Centers for Disease Control and Prevention (CDC) has issued a critical Health Alert Network (HAN) Advisory1 to inform the public about a heightened risk of dengue virus infections within the United States. As we approach the warmer months, it’s crucial for healthcare providers, public health authorities, and individuals to be vigilant and prepared. The advisory emphasizes the importance of preventive measures to mitigate the spread of dengue. This includes the use of mosquito repellents, wearing long-sleeved clothing, and eliminating standing water where mosquitoes breed. Public health officials are urged to monitor and report cases promptly. The CDC’s proactive approach aims to ensure the safety and well-being of communities across the nation. #Dengue #NeglectedDiseases #DrugDiscovery https://lnkd.in/gNN4EyYj
-
DevsHealth is on the lookout for consortium partners for the upcoming EU-funded call for proposals to support the development of novel antivirals (call CP-g-24-105). We offer our expertise on infectious diseases development as well as out state-of-the-art technology, which leverages AI, Real-World Data (RWD), and molecular modeling, to significantly reduce the time, risk, and cost associated with traditional drug discovery methods. Our innovative approach accelerates the drug discovery process, making us a valuable partner to any consortium applying for this call. If you're seeking a partner that can provide advanced digital health solutions and expertise in drug discovery, DevsHealth is ready to join forces and contribute to the success of this important initiative. Let's collaborate to transform the future of healthcare in Europe. #EU4H #PublicHealth #DigitalHealth #DrugDiscovery #Innovation https://lnkd.in/dNmQkQgX
-
-
A great opportunity with a positive impact #DevsHealth
The latest report from the European Centre for Disease Prevention and Control (ECDC) paints a concerning picture of the escalating spread of mosquito-borne diseases within the EU/EEA. The increase in cases of dengue, Zika, and West Nile virus is a public health concern that highlights the need for vigilance and proactive measures. These diseases, often associated with symptoms ranging from mild fever to severe neurological effects, have far-reaching impacts that extend beyond individual health, potentially affecting community well-being and economic stability. The situation calls for a concerted effort to enhance surveillance, improve vector control, and promote public awareness to prevent outbreaks. It also emphasizes the importance of research and development in the field of infectious diseases to better understand the dynamics of transmission and to develop effective prevention and treatment strategies. As we face these challenges, the role of international cooperation becomes ever more critical, ensuring that knowledge and resources are shared to safeguard public health across borders. #InfectiousDiseases #favivirus #mosquito #publichealth https://lnkd.in/d53iTDBt
Worsening spread of mosquito-borne disease outbreaks in EU/EEA, according to latest ECDC figures
ecdc.europa.eu
-
DevsHealth ha compartido esto
DevsHealth is at the forefront of combating flavivirus infections, with a dedicated project focused on developing new antiviral agents. Our innovative approach utilizes cutting-edge AI/ML technology to accelerate the discovery and development process, aiming to create effective and affordable treatments for diseases caused by flaviviruses such as dengue, Zika, and West Nile virus. We're not just developing drugs; we're striving to make a difference in global health. Our project has the potential to save millions of lives and we're actively seeking investors who share our vision. Join us in this vital mission to outsmart flaviviruses and other infections to create a healthier future for all. #JoinTheFight #DevsHealth #InvestInHealth
The latest report from the European Centre for Disease Prevention and Control (ECDC) paints a concerning picture of the escalating spread of mosquito-borne diseases within the EU/EEA. The increase in cases of dengue, Zika, and West Nile virus is a public health concern that highlights the need for vigilance and proactive measures. These diseases, often associated with symptoms ranging from mild fever to severe neurological effects, have far-reaching impacts that extend beyond individual health, potentially affecting community well-being and economic stability. The situation calls for a concerted effort to enhance surveillance, improve vector control, and promote public awareness to prevent outbreaks. It also emphasizes the importance of research and development in the field of infectious diseases to better understand the dynamics of transmission and to develop effective prevention and treatment strategies. As we face these challenges, the role of international cooperation becomes ever more critical, ensuring that knowledge and resources are shared to safeguard public health across borders. #InfectiousDiseases #favivirus #mosquito #publichealth https://lnkd.in/d53iTDBt
Worsening spread of mosquito-borne disease outbreaks in EU/EEA, according to latest ECDC figures
ecdc.europa.eu
-
DevsHealth is at the forefront of combating flavivirus infections, with a dedicated project focused on developing new antiviral agents. Our innovative approach utilizes cutting-edge AI/ML technology to accelerate the discovery and development process, aiming to create effective and affordable treatments for diseases caused by flaviviruses such as dengue, Zika, and West Nile virus. We're not just developing drugs; we're striving to make a difference in global health. Our project has the potential to save millions of lives and we're actively seeking investors who share our vision. Join us in this vital mission to outsmart flaviviruses and other infections to create a healthier future for all. #JoinTheFight #DevsHealth #InvestInHealth
The latest report from the European Centre for Disease Prevention and Control (ECDC) paints a concerning picture of the escalating spread of mosquito-borne diseases within the EU/EEA. The increase in cases of dengue, Zika, and West Nile virus is a public health concern that highlights the need for vigilance and proactive measures. These diseases, often associated with symptoms ranging from mild fever to severe neurological effects, have far-reaching impacts that extend beyond individual health, potentially affecting community well-being and economic stability. The situation calls for a concerted effort to enhance surveillance, improve vector control, and promote public awareness to prevent outbreaks. It also emphasizes the importance of research and development in the field of infectious diseases to better understand the dynamics of transmission and to develop effective prevention and treatment strategies. As we face these challenges, the role of international cooperation becomes ever more critical, ensuring that knowledge and resources are shared to safeguard public health across borders. #InfectiousDiseases #favivirus #mosquito #publichealth https://lnkd.in/d53iTDBt
Worsening spread of mosquito-borne disease outbreaks in EU/EEA, according to latest ECDC figures
ecdc.europa.eu
-
At DevsHealth, we proactively track developments in infectious diseases, guiding our project initiatives beyond market size and economic potential. We're committed to ensuring our endeavors not only succeed commercially but also deliver substantial social benefits. This approach allows us to prioritize health advancements that truly make a difference in the community. #socialimpact #infectiousdiseases #impactcompany #impactinvestment
Mpox is still here, it is not an emergency but it is important to be aware of it. In a recent study led by UCLA, mpox cases have significantly decreased since the 2022 outbreak. However, the data, published by the CDC, indicates that men who have sex with men are still reporting cases. The study involved 196 participants, with no cases reported among women and children. Only three cases were identified, all in men who had multiple male partners in the previous month and were unvaccinated against mpox. Health professionals are advised to remain vigilant, especially with the emergence of a more transmissible and severe mpox clade known as clade 1 in the Democratic Republic of the Congo. Despite the low incidence, experts warn against complacency due to low vaccination rates (23% fully vaccinated) and limited awareness of mpox symptoms and transmission methods. It's crucial to monitor for mpox cases, particularly among those at risk. #mpox #antiviral #viralinfections https://lnkd.in/e3MEWc-c
Mpox Surveillance Based on Rash Characteristics ...
cdc.gov
-
This raises a significant concern, as phage therapy is currently under consideration as a viable strategy to address antimicrobial resistance (AMR). #AMR #PhagesTherapy #MolecularBiology #virus #bacteria
Nature is awesome! Several viruses possess reverse transcriptases that enable them to convert RNA into DNA upon infecting bacteria. However, a novel discovery has revealed that bacteria have their own version of reverse transcriptase. This bacterial enzyme uses RNA as a template to create entirely new DNA genes. These newly minted genes are subsequently transcribed back into RNA and translated into defensive proteins when the bacterium faces viral infection. In contrast, viral reverse transcriptases do not generate new genes; instead, they simply transcribe the information from RNA to DNA. #bacteria #AMR #virus #infections #molecularbiology
Bizarre bacteria defy textbooks by writing new genes
nature.com